Mixed headlines have plagued the cell and gene therapy space of late. We believe that a renewed case of optimism is not only warranted but essential if these therapies are to reach their full potential.
Cell and Gene Therapy Will Transform Lives—If We Let It Read More »
Since July, several biotechs have been forced to pivot as previous agreements with the FDA around evidence required for approval were reversed, a phenomenon that, according to experts, could portend a more restrictive regulator.
FDA Reversals Send UniQure, Biohaven, Capricor, More Into a ‘Tailspin’ Read More »
En cualquier parte nos topamos con los alimentos ultraprocesados: ocupan los estantes del supermercado y hasta se cuelan discretamente en la mesa de reuniones. A pesar de que su conveniencia los hace parecer la solución rápida para el día a día, su consumo habitual genera …
Eleven data exchanges have now received Qualified Health Information Network status, more than double the number that were recognized when the federal government’s framework first went live in late 2023.
Oracle Health designated QHIN under TEFCA data sharing framework Read More »
The proposed deal, the biggest under CEO Robert Ford’s tenure, would allow Abbott to enter a large, new market for cancer testing.
Abbott’s $21B Exact Sciences buy reveals future strategy Read More »
GE HealthCare forecast Intelerad’s revenue to be approximately $270 million in the first full year of ownership. The deal expands GE HealthCare’s presence in more outpatient settings.
The regulator has received reports that a group of patients treated with Adzynma had neutralizing antibodies against the protein the therapy replaces.
FDA Probing Patient Death Linked to Takeda’s Enzyme Replacement Therapy Read More »
After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the regulator’s radar.
6 Biotechs With a Shot at the FDA’s Platform Technology Designation Read More »
Dr. Cristy Page will also serve as dean of the UNC School of Medicine and vice chancellor for medical affairs at UNC-Chapel Hill.
The company has stepped up its interest in M&A since making a $4.1 billion divestiture that strengthened its balance sheet.
